BOIRON
ISIN: FR0000061129 | Ticker: BOI | LEI: 9695000UMPNY21KKDO98
Country: France
Boiron is an independent, family-owned pharmaceutical laboratory specialising in the manufacture of very high quality homeopathic medicines. Present in more than 50 countries (20 subsidiaries), and with more than 2,700 employees, we develop our health project with rigour and passion. For Laboratoires Boiron, health is much more than a business, it is our mission. This is why we produce, in France, effective, risk-free, high-quality health products thanks to our unique pharmaceutical expertise in homeopathy.
We are committed to patients and all health professionals to contribute to a more human, respectful and sustainable medicine.
Our corporate philosophy has always been based on a sincere and shared commitment to improving health, fostering human relations, increasing well-being at work and actively contributing to the protection of our planet.
1932
Served areaWorldwide
Headcount2,700
Headquarters2 Avenue de l'Ouest Lyonnais, 69510 Messimy – France
| Line item in (eur) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 770,700,000.00 | 789,493,000.00 |
| Noncurrent Assets | N/A | 318,336,000.00 | 311,660,000.00 |
| Property Plant And Equipment | N/A | 162,793,000.00 | 152,491,000.00 |
| Goodwill | N/A | 89,635,000.00 | 94,002,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 30,993,000.00 | 31,887,000.00 |
| Deferred Tax Assets | N/A | 21,894,000.00 | 19,130,000.00 |
| Other Noncurrent Assets | N/A | 41,000.00 | 39,000.00 |
| Current Assets | N/A | 452,364,000.00 | 477,833,000.00 |
| Inventories | N/A | 85,556,000.00 | 96,924,000.00 |
| Trade And Other Current Receivables | N/A | 97,340,000.00 | 100,536,000.00 |
| Current Tax Assets Current | N/A | 2,783,000.00 | 1,394,000.00 |
| Cash and cash equivalents | N/A | 234,504,000.00 | 250,945,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | 2,384,000.00 | 1,693,000.00 |
| Other Current Assets | N/A | 29,797,000.00 | 26,341,000.00 |
| Equity And Liabilities | N/A | 770,700,000.00 | 789,493,000.00 |
| Equity | 513,531,000.00 | 531,771,000.00 | 557,346,000.00 |
| Issued Capital | N/A | 17,545,000.00 | 17,545,000.00 |
| Share Premium | N/A | 79,876,000.00 | 79,876,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 531,735,000.00 | 557,616,000.00 |
| Noncontrolling Interests | N/A | 36,000.00 | -270,000.00 |
| Noncurrent Liabilities | N/A | 80,691,000.00 | 78,960,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 71,557,000.00 | 60,759,000.00 |
| Other Longterm Provisions | N/A | 143,000.00 | 143,000.00 |
| Deferred Tax Liabilities | N/A | N/A | 0.00 |
| Other Noncurrent Liabilities | N/A | 1,272,000.00 | 1,320,000.00 |
| Longterm Borrowings | N/A | 2,347,000.00 | 11,564,000.00 |
| Current Liabilities | N/A | 158,238,000.00 | 153,187,000.00 |
| Current Provisions | N/A | 49,884,000.00 | 29,389,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 44,180,000.00 | 48,250,000.00 |
| Current Tax Liabilities Current | N/A | 1,328,000.00 | 2,113,000.00 |
| Other Current Liabilities | N/A | 57,959,000.00 | 68,007,000.00 |
| Line item in (eur) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 455,201,000.00 | N/A |
| Interest Income On Cash And Cash Equivalents | 590,000.00 | 1,817,000.00 |
| Revenue From Contracts With Customers | 455,201,000.00 | 534,239,000.00 |
| Other Income | 1,000.00 | 1,000.00 |
| Profit Loss From Operating Activities | 46,842,000.00 | 63,448,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | N/A | 0.00 |
| Profit Loss Before Tax | 46,113,000.00 | 59,199,000.00 |
| Income Tax Expense Continuing Operations | 17,554,000.00 | 14,919,000.00 |
| Profit (loss) | 28,559,000.00 | 44,280,000.00 |
| Profit Loss Attributable To Owners Of Parent | 28,556,000.00 | 44,673,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 3,000.00 | -393,000.00 |
| Line item in (eur) | 01.01.2022 | 01.01.2023 |
|---|---|---|
| Profit (loss) | 28,559,000.00 | 44,280,000.00 |
| Adjustments For Decrease Increase In Inventories | 1,255,000.00 | -9,801,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | 4,941,000.00 | -959,000.00 |
| Other Adjustments To Reconcile Profit Loss | -8,364,000.00 | -10,426,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 4,304,000.00 | 12,441,000.00 |
| Cash Flows From Used In Operating Activities | 33,317,000.00 | 58,690,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 1,706,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 10,340,000.00 | 7,582,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 10,988,000.00 | 10,237,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | 10,000.00 | 0.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 9,430,000.00 | 8,354,000.00 |
| Cash Flows From Used In Investing Activities | -11,921,000.00 | -15,277,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 6,079,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | 3,000.00 | 22,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | 1,171,000.00 | 963,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 4,401,000.00 | 4,623,000.00 |
| Interest Paid Classified As Financing Activities | 28,000.00 | 53,000.00 |
| Cash Flows From Used In Financing Activities | -21,995,000.00 | -27,577,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -599,000.00 | 15,836,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 368,000.00 | -258,000.00 |
| Cash and cash equivalents | 234,504,000.00 | 250,945,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 20.10.23 | None | Other | Sell | EUR 34,037,282.40 |
| 20.10.23 | None | Other | Sell | EUR 18,351,892.96 |
| 20.10.23 | None | Other | Sell | EUR 10,789,373.76 |
| 20.10.23 | None | Other | Sell | EUR 7,875,040.96 |
| 20.10.23 | None | Other | Sell | EUR 233,876.00 |
| 20.10.23 | None | Other | Sell | EUR 188,210.72 |
| 20.10.23 | None | Other | Sell | EUR 118,047.92 |
FR0000061129
LEI9695000UMPNY21KKDO98
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.